Clinical trial NCT03422445: A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma
Official title: A Phase 2 Study of Apatinib Combined With Temozolomide in the Treatment of Advanced Melanoma Patients After Conventional Treatment Failure
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Advanced Melanoma
Keywords: Apatinib
Temozolomide
Advanced Melanoma
Lead sponsor: Peking University Cancer Hospital & Institute
Sponsor class: OTHER
First posted: 2018-02-05
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: 30 patients with advanced melanoma will receive apatinib plus Temozolomide as maintenance therapy.

Detailed description: In this study, we plan to enroll 30 patients with advanced melanoma patients who have failed at least one systemic treatment regimen. The therapeutic regimen is temozolomide, 300mg,po, d1-5, apatinib, 500 mg, qd, po, d1-28, Every 28 days for 1 cycles, the primary end point was PFS, the secondary end point was OS, DCR, ORR etc. So we plan to investigate the safety and efficacy of apatinib combined with temozolomide in the treatment of advanced melanoma patients.

Eligibility criteria: Inclusion Criteria:

* Age 18-70 years old；
* ECOG performance scale 0-1；
* Life expectancy of more than 3 months；
* Histologically or cytologic confirmed melanoma；
* Temozolomide has not been previously treated；
* Patients who have failed at least one systemic treatment regimen： including but not limited to patients receiving immunotherapeutics such as PD-1 monoclonal antibodies, PDL-1 monoclonal antibodies, ipilimumab, C-kit inhibitors, Braf inhibitors, and molecular targeted drugs.
* For results of blood routine test and biochemical tests： Hgb\>100g/L, ANC\>2.0×109/L, PLT\>100×109/L, Serum Total bilirubin ≤ 1.5 X UNL, ALT and AST ≤ 2.5 x upper normal limit (UNL), and ≤ 5 x UNL（Hematogenous metastases）, Serum Creatine ≤ 1.5 x UNL；
* Informed consent；
* Willingness and ability to comply with scheduled visits.

Exclusion Criteria:

* Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg)；
* With ≥grade 2 coronary heart disease, arrhythmia (including QTc interval prolongation male ≥450 ms, women ≥470 ms)；
* Imaging studies have shown that the tumor has been infringing on an important perivascular or when the researcher determines that the patient's tumor has a high risk of fatal hemorrhage during treatment；
* Abnormal Coagulation (INR\>1.5, PT\>UNL+4 seconds), with tendency of bleed or receiving the therapy of thrombolysis or anticoagulation.；
* Urine protein ≥++ or confirmed \>1.0 g by the 24h quantity；
* Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures；
* A history of psychotropic substance abuse and can not be abstinent or mental disorders ；
* There are serious concomitant diseases that endanger patient safety or affect the patient in completing the study；
* Patients participating in other clinical trials simultaneously；
* Other situations that the researchers considered unsuitable for this study；
* Confirmed brain metastasis.

Primary outcomes:
measure: Progression Free Survival（PFS）
timeFrame: 12 months
Secondary outcomes:
measure: Objective Response Rate(ORR)
timeFrame: 12 months
measure: Disease Control Rate(DCR)
timeFrame: 12 months
measure: Overall Survival(OS)
timeFrame: 12 months
measure: Safety and Tolerability as measured by adverse events
timeFrame: 12 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Cancer Hospital
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Jun Guo, MD，PHD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Zhou L, Yang Y, Si L, Chi Z, Sheng X, Lian B, Wang X, Tang B, Mao L, Yan X, Li S, Bai X, Guo J, Cui C. Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy. Melanoma Res. 2022 Jun 1;32(3):142-149. doi: 10.1097/CMR.0000000000000809. Epub 2022 Feb 20.